Professor, Medicine, Perelman School of Medicine
Oncology
Dr. Roger B. Cohen, MD
|
|
Give Review
Doctor Roger B. Cohen, MD is an expert in the field of Oncology. He went to medical school at Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He received 5 awards: "America's Top Doctors", "Philadelphia Magazine", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Roger B. Cohen is a published physician. He has 47 publications published. The most current publication "Nodal Metastasis and Elective Nodal Level Treatment in Sinonasal Small Cell and Sinonasal Undifferentiated Carcinoma: A Surveillance, Epidemiology and End Results Anal..." He is registered with Medicare.
Publications
- Nodal Metastasis and Elective Nodal Level Treatment in Sinonasal Small Cell and Sinonasal Undifferentiated Carcinoma: A Surveillance, Epidemiology and End Results Anal...
- Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
- A randomized, phase 2 trial of cetuximab with or without PX-866, an irreversible Oral phosphatidylinositol 3-kinase Inhibitor, in patients with relapsed or metastatic ...
- Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors.
- Late Consequential Surgical Bed Soft Tissue Necrosis in Advanced Oropharyngeal Squamous Cell Carcinomas Treated With Transoral Robotic Surgery and Postoperative Radiat...
- A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid Tumors.
- Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous c...
- Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Tria...
- Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
- A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
- A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
- A Web-based communication aid for patients with Cancer: The CONNECT Study.
- Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer.
- Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
- Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid Tumors: phase I study results.
- Increased recurrences using intensity-modulated radiation therapy in the postoperative setting.
- A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung Cancer.
- Impact of neck dissection on long-term feeding tube dependence in patients with head and neck Cancer treated with primary radiation or chemoradiation.
- Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenoCarcinoma.
- Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth fact...
- A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle ...
- Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and ...
- Phase I study of the safety, tolerability, and pharmacokinetics of Oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor...
- Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and phar...
- Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced Cancer and with docetaxel in patients with...
- Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary Gland tumors treated with lapatinib.
- Effects of food on the relative bioavailability of lapatinib in Cancer patients.
- An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid Tumors.
- New agents in the treatment for malignancies of the salivary and thyroid Glands.
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid Cancer: results from a phase II study.
- The role of cetuximab for the treatment of squamous cell Carcinoma of the head and neck.
- Promising survival in patients with recurrent non-small cell lung Cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
- Phase I pharmacokinetic and pharmacodynamic study of the Oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients w...
- EGFR inhibitors for the treatment of squamous cell Carcinoma of the head and neck.
- Clinical application of EGFR inhibitors in head and neck squamous cell Cancer.
- Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic Carcinoma and non adenoid cystic carcino...
- Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung Cancer.
- Quality of life in head and neck Cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
- Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptos...
- The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium.
- Radiotherapy plus cetuximab for squamous-cell Carcinoma of the head and neck.
- Targeting signal transduction pathways in colorectal Cancer--more than skin deep.
- Toxicity and outcome analysis of patients with recurrent head and neck Cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and pa...
- Epidermal growth factor receptor as a therapeutic target in colorectal Cancer.
- Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell Carcinoma.
Schools
Harvard Medical School
Mt Sinai Hospital
National Cancer Institute
Sloan Kettering Ca Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Card PPO
- Capital Blue Cross
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- HealthPartners
- Community Blue PPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- Locals (any local)
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- National Elevator
- Freedom Plan
- Priority Health
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Oxford Liberty
- United Healthcare
- UPMC Health Plan
Awards
- America's Top Doctors
- Philadelphia Magazine
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
National Institutes of Health Clinical Center -
Mount Sinai School of Medicine -
Harvard Medical School
Hospital
-
Hospital of the University of Pennsylvania
Helpful Reviews
Similar Doctors
|
|
Lindsay R. Wilde
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory M. Lubiniecki, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Srikala Addepalli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajan Singla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saar I. Gill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Holly Dushkin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashwin R. Sama, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sameh R. Gaballa, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Neal Flomenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elaine Y. Chiang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sunita D. Nasta, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lynn M. Schuchter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna C. Lysiak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Namrata Vijayvergia, MD
This Doctor is OpenDoctor Recommended.
|